# Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

> **NCT07266766** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 40 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Empagliflozin / Metformin HCl XR Tablets
- **DRUG:** Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)

## Key facts

- **NCT ID:** NCT07266766
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-05
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-10-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266766, "Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07266766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*